These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Crossing the line: part 2. Blaivas JG Neurourol Urodyn; 2005; 24(1):1. PubMed ID: 15593361 [No Abstract] [Full Text] [Related]
14. What ails the FDA? Gorelick KJ N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814 [No Abstract] [Full Text] [Related]
15. The Vioxx debacle. Alpert JS Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713 [No Abstract] [Full Text] [Related]
16. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
17. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
18. Causation, Vioxx, and legal issues. Green MD Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163 [No Abstract] [Full Text] [Related]
19. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals. Lanzafame RJ Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023 [No Abstract] [Full Text] [Related]
20. What happened to the coxibs on the way to the cardiologist? Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326 [No Abstract] [Full Text] [Related] [Next] [New Search]